MRNAModerna, Inc.

Nasdaq modernatx.com


$ 151.50 $ 6.16 (4.24 %)    

Wednesday, 05-Jun-2024 14:48:55 EDT
QQQ $ 454.82 $ 5.31 (1.16 %)
DIA $ 398.57 $ 0.26 (0.07 %)
SPY $ 530.36 $ 3.17 (0.6 %)
TLT $ 91.26 $ 0.17 (0.19 %)
GLD $ 225.37 $ 1.26 (0.58 %)
$ 145.34
$ 145.87
$ 148.00 x 114
$ 151.49 x 106
$ 145.00 - $ 153.62
$ 62.55 - $ 170.47
3,045,560
na
55.52B
$ 0.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 10-30-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-novavax-stock

Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look...

 moderna-says-it-is-prepared-to-submit-for-approval-a-covid-vaccine-targeting-either-jn1-or-kp2-variant

- Reuters

 promising-trial-results-show-new-standards-in-cancer-treatment-and-diagnostics-are-on-the-horizon

On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a...

 rbc-capital-maintains-outperform-on-moderna-raises-price-target-to-160

RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $135 to $160.

Core News & Articles

https://www.youtube.com/watch?v=qCsEbq9SpsM 

 moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-patients

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free an...

Core News & Articles

- Reuters - Reuters 

Core News & Articles

With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination wit...

 needham-reiterates-hold-on-moderna

Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.

 moderna-scores-fda-approval-for-its-second-product---respiratory-syncytial-virus-vaccine

FDA approves Moderna's mRESVIA (mRNA-1345), an mRNA vaccine for RSV, for adults 60+. The second approved mRNA product from ...

Core News & Articles

https://www.ft.com/content/fad59eb1-2f34-47eb-b938-49ed12f12c45

 cathie-wood-led-ark-invest-cuts-robinhood-holdings-amid-bitcoin-dip-keeps-selling-moderna-stock--buys-palantir-and-amd-shares

On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc ...

 vix-rises-8-treasury-yields-jump-dow-plunges-why-is-wall-street-wobbling-wednesday-corrected

Wall Street opens with red showing as investors worry about interest rates. Volatility and Treasury yields spike. Traders expec...

 whats-going-on-with-moderna-stock-today

Moderna Inc. (NASDAQ: MRNA) shares are trading lower Tuesday. The stock may be pulling back after gaining on bird flu concerns ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION